Abstract
Bone metastasis (BM) is a frequent complication in patients with advanced lung cancer and it causes skeletal-related events (SREs). Our study aim is to prospectively investigate the incidence of BM, incidence and types of SRE, and predictive factors of BM and SREs. Newly diagnosed, advanced non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) patients were enrolled into the study. Patients were followed up every 4 weeks to monitor the development of SREs. Treatment for lung cancer was performed at the discretion of the investigator. Two hundred seventy-four patients were enrolled in this study between April 2007 and December 2009 from 12 institutions. Patients included 77 cases of SCLC and 197 of NSCLC (stage IIIB/IV = 73/124). Median follow-up time was 13.8 months. The incidence of BM at initial diagnosis was 48% in stage IV NSCLC and 40% in extensive stage (ED)-SCLC. Forty-five percent of patients who developed BM had SREs consisting of pathologic fracture (4.7%), radiation to bone (15.3%), spinal cord compression (1.1%), and hypercalcemia (2.2%). Multivariate analysis revealed that factors predicting BM are stage IV, performance status 1 or greater and higher bone alkaline phosphatase in NSCLC patients, higher lactate dehydrogenase, and lower parathyroid hormone-related peptide in SCLC patients. Factors predicting SREs were stage IV, age 64 or younger, and lower albumin in NSCLC patients. Multivariate analysis of SRE was not performed for SCLC because of the small number of events. Predictive factors should be taken into consideration in future randomized studies evaluating BM and SREs.
MeSH Terms
Adult
Aged
Aged, 80 and over
Bone Neoplasms/epidemiology,secondary
Carcinoma, Non-Small-Cell Lung/secondary
Female
Follow-Up Studies
Fractures, Spontaneous/pathology
Humans
Hypercalcemia/pathology
Incidence
Japan/epidemiology
Lung Neoplasms/pathology
Male
Middle Aged
Neoplasm Staging
Prognosis
Prospective Studies
Small Cell Lung Carcinoma/secondary
Spinal Cord Compression/pathology
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Katakami Nobuyuki
*Institute of Biomedical Research and Innovation, Kobe, Japan; †Yokohama Municipal Citizen's Hospital, Yokohama, Japan; ‡Osaka City General Hospital, Osaka, Japan; §Kyushu University Hospital, Fukuoka, Japan; ‖Gifu Municipal Hospital, Gifu, Japan; ¶Aichi Cancer Center Aichi Hospital, Okazaki, Japan; #National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; **Toneyama National Hospital, Toyonaka, Japan; ††Tokai University School of Medicine, University Hospital, Isehara, Japan; ‡‡Shizuoka Cancer Center, Shizuoka, Japan; §§The University of Tokyo, Tokyo, Japan; and ‖‖Teikyo University School of Medicine, Tokyo, Japan.
Kunikane Hiroshi
Takeda Koji
Takayama Koichi
Sawa Toshiyuki
Saito Hiroshi
Harada Masao
Yokota Soichiro
Ando Kiyoshi
Saito Yuko
Yokota Isao
Ohashi Yasuo
Eguchi Kenji
References (24)
24 references, click to expand
-
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Ann Oncol. 2015 Jul;26(7):1401-8
PMID: 25908605
-
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.
Lung Cancer. 2012 Sep;77(3):572-7
PMID: 22672969
-
Bone resorption predicts for skeletal complications in metastatic bone disease.
Br J Cancer. 2003 Dec 1;89(11):2031-7
PMID: 14647134
-
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
Clin Chem. 1999 Aug;45(8 Pt 1):1240-7
PMID: 10430790
-
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
J Natl Cancer Inst. 2005 Jan 5;97(1):59-69
PMID: 15632381
-
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
N Engl J Med. 1999 Jan 28;340(4):265-71
PMID: 9920950
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
N Engl J Med. 2002 Jan 10;346(2):92-8
PMID: 11784875
-
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
J Clin Oncol. 2011 Mar 20;29(9):1125-32
PMID: 21343556
-
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
J Clin Oncol. 2006 May 1;24(13):2038-43
PMID: 16648503
-
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Lung Cancer. 2004 Jun;44(3):317-25
PMID: 15140545
-
Metastatic bone disease: clinical features, pathophysiology and treatment strategies.
Cancer Treat Rev. 2001 Jun;27(3):165-76
PMID: 11417967
-
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
N Engl J Med. 1996 Dec 12;335(24):1785-91
PMID: 8965890
-
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
N Engl J Med. 2002 Jan 10;346(2):85-91
PMID: 11784874
-
Skeletal metastases in non-small cell lung cancer: a retrospective study.
Lung Cancer. 2007 Aug;57(2):229-32
PMID: 17451841
-
Metastasis to bone: causes, consequences and therapeutic opportunities.
Nat Rev Cancer. 2002 Aug;2(8):584-93
PMID: 12154351
-
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
J Clin Oncol. 1986 May;4(5):702-9
PMID: 3701389
-
Biochemical prediction of response of bone metastases to treatment.
Br J Cancer. 1988 Aug;58(2):205-10
PMID: 3262366
-
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ann Oncol. 2007 Feb;18(2):317-23
PMID: 17079694
-
The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition.
J Thorac Oncol. 2008 May;3(5):457-66
PMID: 18448996
-
Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.
J Clin Oncol. 2005 Jan 1;23(1):175-83
PMID: 15625371
-
FDG-PET imaging for the staging and follow-up of small cell lung cancer.
Eur J Nucl Med. 2001 Apr;28(4):483-8
PMID: 11357499
-
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.
Curr Opin Oncol. 2008 Mar;20(2):155-61
PMID: 18300765
-
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.
J Clin Oncol. 2002 Jul 15;20(14):3054-60
PMID: 12118018
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
J Clin Oncol. 2003 Aug 15;21(16):3150-7
PMID: 12915606